Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354428 · ClinicalTrials.gov registry record · Phase 2
Treatment for COVID-19 in High-Risk Adult Outpatients
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT04354428 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 289 participants.
The verdict
NCT04354428, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Interventions
- DRUG Azithromycin
- DRUG Ascorbic Acid
- DRUG Folic Acid
- DRUG Hydroxychloroquine Sulfate
- DRUG Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354428
The ClinicalTrials.gov registry entry for NCT04354428 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Azithromycin is the first listed.
NCT04354428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04354428 about?
NCT04354428 is a clinical study titled "Treatment for COVID-19 in High-Risk Adult Outpatients". This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract i...
What is the current status of trial NCT04354428?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2020-04-16. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT04354428?
The interventions under investigation include: Azithromycin (DRUG), Ascorbic Acid (DRUG), Folic Acid (DRUG), Hydroxychloroquine Sulfate (DRUG), Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] (DRUG).
Who is sponsoring clinical trial NCT04354428?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.